IDXX IDEXX LABORATORIES INC /DE

Nasdaq In Vitro & In Vivo Diagnostic Substances DE CIK: 0000874716
AI RATING
STRONG_BUY
78% Confidence

Investment Thesis

IDXX demonstrates exceptional fundamental strength with highly profitable operations (63% gross margin, 32% operating margin) generating robust free cash flow of $234M while maintaining a fortress balance sheet with minimal leverage (0.19x debt/equity). Earnings growth (19.3% net income, 22.6% EPS) is accelerating ahead of revenue growth (10.4%), indicating strong operational leverage and improved execution.

Strengths

  • + Exceptional profitability: 63.4% gross margin, 31.8% operating margin, 24.4% net margin indicate pricing power and operational excellence
  • + Accelerating earnings growth: 22.6% EPS growth and 19.3% net income growth significantly outpace 10.4% revenue growth, showing operational leverage
  • + Strong free cash flow generation: $234M FCF with 20.5% FCF margin provides significant capital deployment flexibility
  • + Conservative balance sheet: 0.19x debt/equity ratio and 45.8x interest coverage demonstrate minimal financial risk
  • + Solid return on equity: 17.9% ROE demonstrates effective capital deployment

Risks

  • ! Working capital concerns: Quick ratio of 0.82x below 1.0 suggests potential liquidity constraints or inventory buildup requiring monitoring
  • ! Current ratio of 1.12x is modest and may limit financial flexibility in adverse scenarios
  • ! Diagnostics market competition and potential healthcare regulatory headwinds not reflected in recent metrics

Key Metrics to Watch

Financial Metrics

Revenue
1.1B
Net Income
278.4M
EPS (Diluted)
$3.47
Free Cash Flow
234.3M
Total Assets
3.4B
Cash
200.5M

Profitability Ratios

Gross Margin 63.4%
Operating Margin 31.8%
Net Margin 24.4%
ROE 17.9%
ROA 8.2%
FCF Margin 20.5%

Balance Sheet & Liquidity

Current Ratio
1.12x
Quick Ratio
0.82x
Debt/Equity
0.19x
Debt/Assets
54.0%
Interest Coverage
45.83x
Long-term Debt
299.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T09:18:22.375198 | Data as of: 2026-03-31 | Powered by Claude AI